Goldman Sachs’s $113 target on ABT

ABT Abbott Laboratories

$90.5 → $113 (+25%) by Jun 2027

Buy · lowers · said Jun 8, 2026 · 12-month default horizon

Open: judged on the close on Jun 8, 2027

The article this target came from

Goldman Sachs Maintains Buy Rating on Abbott Laboratories (ABT) Stock

Yahoo Finance · Jun 8, 2026

reduced the price objective to $113.00 from $121.00.

Goldman Sachs’s track record → Abbott Laboratories →

A fact about what Goldman Sachs published, as reported by Yahoo Finance, not a recommendation from Dalsna Finance; Goldman Sachs is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.